AMIDEBIO Granted Orphan Drug Designation by FDA for Novel Solution Stable Glucagon

AmideBio, LLC, a privately held biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) Office of Orphan Products Development granted an orphan drug designation to AmideBio’s glucagon analog (ABG-023) for the treatment of congenital hyperinsulinism (CHI). ABG-023 is a solution stable, soluble glucagon analog designed to overcome the limitations of glucagon – an effective treatment for CHI, but rendered impractical for long term administration given its instability in solution. Read the full press release.